Addressing the challenge of extended-spectrum β-lactamases

Current Opinion in Investigational Drugs

Volumn 10, Issue 2, 2009, Pages 172-180

  Zahar, J R ^a   Lortholary, O ^a   Martin, C ^b   Potel, G ^c   Plesiat, P ^d   Nordmann, P ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

CTX M; Extended spectrum lactamase; Infection control; Multidrug resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN TROMETAMOL; GENTAMICIN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TEMOCILLIN; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIUM DETECTION; BACTERIUM ISOLATION; CYSTITIS; DRUG CHOICE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; INFECTION CONTROL; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PROSTATITIS; PYELONEPHRITIS; REVIEW; SEPTIC SHOCK; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 62249095611     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control (2004) 32(8):470-485.
2. DiPersio JR, Deshpande LM, Biedenbach DJ, Toleman MA, Walsh TR, Jones RN: Evolution and dissemination of extended-spectrum β-lactamase- producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis (2005) 51(1):1-7.
3. Paterson DL: Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med (2006) 119(6 Suppl 1):S20-S28.
4. Cantón R, Coque TM: The CTX-M β-lactamase pandemic. Curr Opin Microbiol (2006) 9(5):466-475. •• This paper eloquently summarizes the distribution of CTX-M in Enterobacteriaceae worldwide.
5. Rossolini GM, D'Andrea MM, Mugnaioli C: The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect (2008) 14(Suppl 1):33-41.
6. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1983) 11(6):315-317. • The first report on ESBLs.
7. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R: Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother (1987) 20(3):323-334.
8. Yuan M, Aucken H, Hall LM, Pitt TL, Livermore D: Epidemiological typing of Klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother (1998) 41(5):527-539.
9. Lucet JC, Decré D, Fichelle A, Joly-Guillou ML, Pernet M, Dblanchy C, Kosmann MJ, Régnier B: Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis (1999) 29(6):1411-1418.
10. Babini GS, Livermore DM: Antimicrobial resistance amongst Klebsiella spp collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother (2000) 45(2):183-189.
11. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ: CTX-M-type β-lactamases: An emerging group of extended-spectrum enzymes. Int J Antimicrob Agents (2000) 14(2):137-142. •• An excellent review on CTX-M-type enzymes.
12. Baraniak A, Fiett J, Hryniewicz W, Nordmann P, Gniadkowski M: Ceftazidime-hydrolysing CTX-M-15 extended-spectrum β-lactamase (ESBL) in Poland. J Antimicrob Chemother (2002) 50(3):393-396.
13. 167T substitution in the active-site omega loop associated with ceftazidime resistance. J Antimicrob Chemother (2004) 54(2):406-409.
14. Glupczynski Y, Huang TD, Berhin C, Claeys G, Delmée M, Ide L, Ieven G, Pierard D, Rodriguez-Villalobos H, Struelens M, Vaneldere J: In vitro activity of temocillin against prevalent extended-spectrum β-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis (2007) 26(11):777-783.
15. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y: Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother (1993) 37(4):851-858.
16. Mendonça N, Louro D, Castro AP, Diogo J, Caniça AM: CTX-M-15, OXA-30 and TEM-1-producing Escherichia coli in two Portuguese regions. J Antimicrob Chemother (2006) 57(5):1014-1006.
17. Paterson DL, Bonomo RA: Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev (2005) 18(4):657-686.
18. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Canton R: Antibiotic coresistance in extended-spectrum- β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother (2006) 50(8):2695-2699.
19. Nicolas-Chanoine MH, Jarlier V; La Collegiale de Bactériologie- Virologie-Hygiène hospitalière de l'Assistance Publique Hôpitaux de Paris: Extended-spectrum β-lactamases in long-term-care facilities. Clin Microbiol Infect (2008) 14(Suppl 1):111-116.
20. Nordmann P, Poirel L: Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother (2005) 56(3):463-469.
21. Karim A, Poirel L, Nagarajan S, Nordmann P: Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett (2001) 201(2):237-241. • The first report on CTX-M-15.
22. Kader AA, Kumar A, Kamath KA: Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol (2007) 28(9):1114-1116.
23. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, Leavitt A, Carmeli Y: Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis (2006) 42(7):925-934.
24. Valverde A, Coque TM, Sánchez-Moreno MP, Rollan A, Canton R, Baquero F: Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol (2004) 42(10):4769-4775. • An excellent paper discussing the importance of ESBL fecal carriage.
25. Grobost F, Quentin C, Arpin C: Epidémiologie des Entérobactéries productrices de β-lactamases à spectre élargi (EBLSE) communautaires en France: Enquête trans-réseaux dans les laboratoires de ville. 26th Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, Paris, France (2006).
26. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC, Hebden JN, Morris JG Jr: Risk factors for colonization with extended-spectrum β-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis (2007) 13(8):1144-1149.
27. Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G: CTX-M-5, a novel cefotaxime-hydrolyzing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob Agents Chemother (1998) 42(8):1980-1984.
28. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N: CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother (2007) 59(2):165-174. •• This collaborative paper details the spread of CTX-Ms throughout Europe.
29. Bernard H, Tancrede C, Livrelli V, Morand A, Barthélémy M, Labia R: A novel plasmid-mediated extended-spectrum β-lactamase not derived from TEM- or SHV-type enzymes. J Antimicrob Chemother (1992) 29(5):590-592. •• This paper reported the first enzyme of the CTX-M type.
30. Brasme L, Nordmann P, Fidel F, Lartigue MF, Bajolet O, Poirel L, Forte D, Vernet-Garnier V, Madoux J, Reveil JC, Alba-Sauviat C et al: Incidence of class A extended-spectrum β-lactamases in Champagne-Ardenne (France): A 1 year prospective study. J Antimicrob Chemother (2007) 60(5):956-964.
31. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM: Prevalence and spread of extended-spectrum β-lactamase- producing Enterobacteriaceae in Europe. Clin Microbiol Infect (2008) 14(Suppl 1):144-153.
32. Lau SH, Kaufmann ME, Livermore DM, Woodford N, Willshaw GA, Cheasty T, Stamper K, Reddy S, Cheesbrough J, Bolton FJ, Fox AJ, Upton M: UK epidemic Escherichia coli strains A-E, with CTX-M-15 β-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother (2008) 62(6):1241-1244.
33. Woodford N, Kaufmann ME, Karisik E, Hartley JW: Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England. J Antimicrob Chemother (2007) 59(1):106-109.
34. Potz NA, Hope R, Warner M, Johnson AP, Livermore DM; London and South East ESBL Project Group: Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother (2006) 58(2):320-326.
35. Carattoli A: Animal reservoirs for extended spectrum β-lactamase producers. Clin Microbiol Infect (2008) 14(Suppl 1):117-123. • An overview of ESBL producers in animals.
36. Warren RE, Ensor VM, O'Neill P, Butler V, Taylor J, Nye K, Harvey M, Livermore DM, Woodford N, Hawkey PM: Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum β-lactamases in the UK. J Antimicrob Chemother (2008) 61(3):504-508.
37. Peña C, Gudiol C, Tubau F, Saball M, Pujol M, Dominguez MA, Calatayud L, Ariza J, Gudiol F: Risk-factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect (2006) 12(3):279-284.
38. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E: Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: Risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol (2002) 23(5):254-260.
39. Asensio A, Oliver A, González-Diego P, Pérez-Díaz JC, Ros P, Cobo J, Palacios M, Lasheras D, Cantón R: Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: Antibiotic use as risk factor for colonization and infection. Clin Infect Dis (2000) 30(1):55-60.
40. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R: Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis (2004) 23(3):163-167.
41. Zahar JR, Lecuit M, Carbonnelle E, Ribadeau-Dumas F, Nassif X, Lortholary O: Is it time to reconsider initial antibiotic treatment strategies for severe urinary tract infections in Europe? Clin Microbiol Infect (2007) 13(3):219-221.
42. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J: Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J Antimicrob Chemother (2006) 57(4):780- 783.
43. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Perea EJ, Pérez-Cano R, Hernández JR, Pascual A: Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: Implications for control. Clin Infect Dis (2006) 42(1):37-45.
44. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M, Gálvez J, Perea EJ, Pascual A: Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect (2008) 14(2):180-183.
45. Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, Cavalie L, Jean-Pierre H, Bonnet R, Sotto A: CTX-M β-lactamase- producing Escherichia coli in French hospitals: Prevalence, molecular epidemiology, and risk factors. J Clin Microbiol (2007) 45(2):620-626.
46. Thouverez M, Talon D, Bertrand X: Control of Enterobacteriaceae producing extended-spectrum β-lactamase in intensive care units: Rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol (2004) 25(10):838- 841.
47. Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, Noskin GA, Zembower T: Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis (2007) 45(7):846-852.
48. Drieux L, Brossier F, Sougakoff W, Jarlier V: Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: Review and bench guide. Clin Microbiol Infect (2008) 14(Suppl 1):90-103.
49. Stelfox HT, Bates DW, Redelmeier DA: Safety of patients isolated for infection control. J Am Med Assoc (2003) 290(14):1899-1905.
50. Kassis-Chikhani N, Vimont S, Asselat K, Trivalle C, Minassian B, Sengelin C, Gautier V, Mathieu D, Dussaix E, Arlet G: CTX-M β-lactamase- producing Escherichia coli in long-term care facilities, France. Emerg Infect Dis (2004) 10(9):1697-1698.
51. Kiratisin P, Apisarnthanarak A, Saifon P, Laesripa C, Kitphati R, Mundy LM: The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum β-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn Microbiol Infect Dis (2007) 58(3):349-355.
52. Karisik E, Ellington MJ, Livermore DM, Woodford N: Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum β-lactamases in the UK. J Antimicrob Chemother (2008) 61(1):54-58.
53. Norris DL, Young JD: Urinary tract infections: Diagnosis and management in the emergency department. Emerg Med Clin North Am (2008) 26(2):413-430.
54. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC: Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother (2002) 46(5):1481-1491.
55. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 39(6):2206- 2212.
56. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L et al: Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother (2003) 47(11):3442-3447.
57. Akova M: Sulbactam-containing β-lactamase inhibitor combinations. Clin Microbiol Infect (2008) 14(Suppl 1):185-188.
58. Bin C, Hui W, Renyuan Z, Yongzhong N, Xiuli X, Yingchun X, Yuanjue Z, Minjun C: Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis (2006) 56(4):351-357.
59. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum β-lactamases. Clin Infect Dis (2004) 39(1):31-37.
60. Peterson LR: Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: The role of piperacillin-tazobactam. Clin Microbiol Infect (2008) 14(Suppl 1):181-184.
61. MacGowan A: Breakpoints for extended-spectrum β-lactamase- producing Enterobacteriacae: Pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect (2008) 14(Suppl 1):166-168.
62. Pangon B, Bizet C, Buré A, Pichon F, Philippon A, Regnier B, Gutmann L: In vivo selection of a cephamycin resistant, porin deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis (1989) 159(5):1005-1006. • This paper was one of the first to describe the presence of a combined mechanism of resistance in an ESBL producer.
63. Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomás JM, Benedi VJ, Jacoby GA: In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother (1996) 40(2):342-348.
64. Gazouli M, Kaufmann ME, Tzelepi E, Dimopoulou H, Paniara O, Tzouvelekis LS: Study of an outbreak of cefoxitin-resistant Klebsiella pneumoniae in a general hospital. J Clin Microbiol (1997) 35(2):508-510.
65. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N: Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from South-East England. J Antimicrob Chemother (2006) 57(5):1012-1014.
66. Rodriguez-Villalobos H, Malaviolle V, Frankard J, De Mendonça R, Nonhoff C, Struelens MJ: In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother (2006) 57(4):771-774.
67. Graninger W: Pivmecillinam - Therapy of choice for lower urinary tract infection. Int J Antimicrob Agents (2003) 22 (Suppl 2):73-78.
68. Kerrn MB, Frimodt-Møller N, Espersen F: Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clin Microbiol Infect (2004) 10(1):54-61.
69. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore DM: Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother (2006) 57(2):367-368.
70. Shah PM: Parenteral carbapenems. Clin Microbiol Infect (2008) 14(Suppl 1):175-180.
71. Livermore DM, Oakton KJ, Carter MW, Warner M: Activity of ertapenem (MK-0826) versus enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother (2001) 45(10):2831-2837. • An informative study that details the activity of ertapenem against a variety of ESBL producers.
72. Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP: Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp from Brazil. Int J Antimicrob Agents (2006) 28(4):340-344.
73. Colodner R, Samra Z, Keller N, Sprecher H, Block C, Peled N, Lazarovitch T, Bardenstein R, Schwartz-Harari O, Carmeli Y; Israel ESBL Group: First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp to antimicrobials in Israel. Diagn Microbiol Infect Dis (2007) 57(2):201-205.
74. DiNubile MJ, Friedland IR, Chan CY, Motyl MR, Giezek H, McCarroll K, Shivaprakash M, Quinn JP, Weinstein RA, Chow JW: Bowel colonization with vancomycin-resistant Enterococci after antimicrobial therapy for intra-abdominal infections: Observations from 2 randomized comparative clinical trials of ertapenem therapy. Diagn Microbiol Infect Dis (2007) 58(4):491-494.
75. Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, Weinstein RA, Quinn JP: Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: Observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis (2005) 24(7):443-449.
76. DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H: Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother (2005) 49(8):3217-3221.
77. Girlich D, Poirel L, Nordmann P: CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (2009): doi:10.1128/AAC.01007-08.
78. De Cueto M, López L, Hernández JR, Morillo C, Pascual A: In vitro activity of fosfomycin against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob Agents Chemother (2006) 50(1):368-370.
79. Slover CM, Rodvold KA, Danziger LH: Tigecycline: A novel broad spectrum antimicrobial. Ann Pharmacother (2007) 41(6):965-972.
80. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Cantón R: Antibiotic coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother (2006) 50(8):2695-2699.